219 related articles for article (PubMed ID: 36077491)
1. Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.
Pilszyk A; Niebrzydowska M; Pilszyk Z; Wierzchowska-Opoka M; Kimber-Trojnar Ż
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077491
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Tahrani AA; Piya MK; Barnett AH
Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
[TBL] [Abstract][Full Text] [Related]
3. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies in type 2 diabetes mellitus.
Chia CW; Egan JM
J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
6. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
9. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
10. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
11. Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus.
Salami R; Salami M; Mafi A; Aarabi MH; Vakili O; Asemi Z
Curr Mol Pharmacol; 2023; 16(4):448-464. PubMed ID: 36043753
[TBL] [Abstract][Full Text] [Related]
12. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
13. The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.
Chen C; Huang Y; Dong G; Zeng Y; Zhou Z
Gynecol Endocrinol; 2020 May; 36(5):375-380. PubMed ID: 31858859
[TBL] [Abstract][Full Text] [Related]
14. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for gestational diabetes.
Patti AM; Giglio RV; Pafili K; Rizzo M; Papanas N
Expert Opin Pharmacother; 2018 Sep; 19(13):1407-1414. PubMed ID: 30136869
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
18. Incretins, Pregnancy, and Gestational Diabetes.
Nikolic D; Al-Rasadi K; Al Busaidi N; Al-Waili K; Banerjee Y; Al-Hashmi K; Montalto G; Rizvi AA; Rizzo M; Al-Dughaishi T
Curr Pharm Biotechnol; 2016; 17(7):597-602. PubMed ID: 26813306
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
20. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
